LEADER 01169nam1-22003011i-450- 001 990002209890403321 005 20070508125224.0 035 $a000220989 035 $aFED01000220989 035 $a(Aleph)000220989FED01 035 $a000220989 100 $a20030910d1965----km-y0itay50------ba 101 0 $aita 200 1 $a1st International symposium on radiosensitizers and radioprotective drugs, Milan 1964$forganized by the European Society for Biochemical Pharmacology$gedited by R. Paoletti and R. Vertua 210 $aBasel$cS. Karger$d1965 215 $aX, 750 p., tav.$cill.$d24 cm 225 1 $aProgress in biochemical pharmacology$v1 702 1$aPaoletti,$bRodolfo$f<1931- > 702 1$aVertua,$bR. 710 12$aInternational Symposium on Radiosensitizers and Radioprotective Drugs$d<1. ;$f1964 ;$eMilano>$0427508 712 02$aEuropean Society for Biochemical Pharmacology 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990002209890403321 952 $a80 XIV D 23(1)$b1526$fFFABC 959 $aFFABC 996 $a1st International symposium on radiosensitizers and radioprotective drugs, Milan 1964$9395784 997 $aUNINA LEADER 04672nam 2200661 450 001 9910136781303321 005 20200520144314.0 010 $a1-119-03910-X 010 $a1-119-03909-6 035 $a(CKB)3710000000635960 035 $a(EBL)4498643 035 $a(SSID)ssj0001647953 035 $a(PQKBManifestationID)16417130 035 $a(PQKBTitleCode)TC0001647953 035 $a(PQKBWorkID)14971213 035 $a(PQKB)10538873 035 $a(PQKBManifestationID)16422289 035 $a(PQKB)23486824 035 $a(MiAaPQ)EBC4498643 035 $a(DLC) 2015048297 035 $a(Au-PeEL)EBL4498643 035 $a(CaPaEBR)ebr11201305 035 $a(CaONFJC)MIL913561 035 $a(OCoLC)931861491 035 $a(PPN)261797603 035 $a(EXLCZ)993710000000635960 100 $a20160426h19962016 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aPulmonary embolism /$fby Paul D. Stein 205 $aThird edition. 210 1$aChichester, [England] :$cWiley Blackwell,$d1996. 210 4$dİ2016 215 $a1 online resource (1186 p.) 300 $aDescription based upon print version of record. 311 $a1-119-03911-8 311 $a1-119-03908-8 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aTitle Page; Copyright; Table of Contents; Dedication; Prologue; The ancient history of deep venous thrombosis and pulmonary embolism; References; Preface to the Third Edition; About the companion website; Introduction; References; Part I: Prevalence, risks, and prognosis of pulmonary embolism and deep venous thrombosis; Chapter 1: Pulmonary embolism and deep venous thrombosis at autopsy; Prevalence of pulmonary embolism at autopsy; Large or fatal PE at autopsy; Small PE at autopsy; Unsuspected PE at autopsy; Rate and sequence of organization of thromboemboli; Deep venous thrombosis at autopsy 327 $aForward thrombosis versus retrograde thrombosisCollateral veins around occlusions; Thrombophlebitis and phlebothrombosis; Valve pockets as site of origin of DVT; References; Chapter 2: Incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients and in emergency departments; Pulmonary embolism in hospitals; Pulmonary embolism in emergency departments; Deep venous thrombosis in hospitals; Deep venous thrombosis in emergency departments; Vena cava thrombosis; References 327 $aChapter 3: Case fatality rate and population mortality rate from pulmonary embolism and deep venous thrombosisCase fatality rate of patients with pulmonary embolism before early diagnosis by imaging was available; Case fatality rate of untreated patients with pulmonary embolism in the present era; Case fatality rate of patients with deep venous thrombosis; Treated patients with pulmonary embolism compared with treated patients with deep venous thrombosis; Case fatality rate of pulmonary embolism in the present era; Stable patients with pulmonary embolism 327 $aUnstable patients with pulmonary embolismEarly death from pulmonary embolism; Case fatality rate attributable to pulmonary embolism; Case fatality rate according to age; Population mortality rate from PE; References; Chapter 4: Prognosis in acute pulmonary embolism based on right ventricular enlargement and biochemical markers in stable patients; Right ventricular enlargement and prognosis in stable patients; Cardiac troponins and prognosis; Cardiac troponin levels in combination with right ventricular dysfunction or right ventricular dilatation 327 $aRandomized controlled trial: thrombolytic therapy in patients with elevated cardiac troponin and RV dysfunctionMyoglobin; Natriuretic peptides; Serum uric acid; Creatine kinase isoenzyme MB; Plasma heart-type fatty acid binding protein; References; Chapter 5: Prognosis in acute pulmonary embolism based on scoring systems; Identification of high-risk patients; Identification of low-risk patients potentially eligible for home treatment of PE; Comparison of outcome in low-risk patients according to scoring system; Cardiac biomarkers for assessment of low risk; References 327 $aChapter 6: Pulmonary embolism following deep venous thrombosis and outcome with untreated pulmonary embolism 606 $aPulmonary embolism 615 0$aPulmonary embolism. 676 $a616.249 700 $aStein$b Paul D.$0964968 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910136781303321 996 $aPulmonary embolism$92189335 997 $aUNINA